Harmony Biosciences (HRMY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $37.95, -0.84% vs the prior close of $38.27.
- Volume 892.25K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
HRMY dips 0.8% to $37.95. Closed at $37.95, -0.84% vs the prior close of $38.27. Day range $37.85–$39.00, opened at $38.47.
HRMY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — HRMY dips 0.8% to $37.95
- Closed at $37.95, -0.84% vs the prior close of $38.27. Day range $37.85–$39.00, opened at $38.47.
- Volume was 892.25K shares, 1.0x its 50-day average of 878.17K.
- Price is -5.1% vs its 50-day average ($39.98) and +9.5% vs its 200-day average ($34.67).
- 52-week range $25.52–$43.49; today's close sits at 69% of that range, 12.7% below the 52-week high.
Oct 15, 2026 — HRMY rises 2.0% to $38.27
- Closed at $38.27, +2.03% vs the prior close of $37.51. Day range $38.00–$39.00, opened at $38.04.
- Volume was 798.30K shares, 0.9x its 50-day average of 887.84K.
- Price is -4.3% vs its 50-day average ($40.00) and +10.4% vs its 200-day average ($34.66).
- 52-week range $25.52–$43.49; today's close sits at 71% of that range, 12.0% below the 52-week high.
Oct 14, 2026 — HRMY rises 1.3% to $37.51
- Closed at $37.51, +1.30% vs the prior close of $37.03. Day range $36.92–$38.31, opened at $37.16.
- Volume was 972.20K shares, 1.1x its 50-day average of 908.23K.
- Price is -6.2% vs its 50-day average ($40.00) and +8.2% vs its 200-day average ($34.66).
- 52-week range $25.52–$43.49; today's close sits at 67% of that range, 13.8% below the 52-week high.
Oct 13, 2026 — HRMY slides 3.1% to $37.03, a 1-month low
- Closed at $37.03, -3.14% vs the prior close of $38.23. Day range $35.99–$38.17, opened at $37.91.
- Volume was 1.42M shares, 1.6x its 50-day average of 897.50K.
- Price is -7.5% vs its 50-day average ($40.02) and +6.8% vs its 200-day average ($34.67).
- 52-week range $25.52–$43.49; today's close sits at 64% of that range, 14.9% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — HRMY slides 5.1% to $38.23, a 1-month low
- Closed at $38.23, -5.09% vs the prior close of $40.28. Day range $37.01–$39.89, opened at $38.34.
- Volume was 1.15M shares, 1.3x its 50-day average of 886.63K.
- Price is -4.4% vs its 50-day average ($39.99) and +10.3% vs its 200-day average ($34.67).
- 52-week range $25.52–$43.49; today's close sits at 71% of that range, 12.1% below the 52-week high.
Oct 9, 2026 — HRMY rises 1.7% to $40.28
- Closed at $40.28, +1.72% vs the prior close of $39.60. Day range $39.51–$40.57, opened at $39.53.
- Volume was 487.10K shares, 0.5x its 50-day average of 888.93K — lighter than usual.
- Price is +0.9% vs its 50-day average ($39.93) and +16.2% vs its 200-day average ($34.67).
- 52-week range $25.52–$43.49; today's close sits at 82% of that range, 7.4% below the 52-week high.
Oct 8, 2026 — HRMY rises 0.7% to $39.60
- Closed at $39.60, +0.66% vs the prior close of $39.34. Day range $38.68–$39.89, opened at $39.14.
- Volume was 865.00K shares, 1.0x its 50-day average of 880.97K.
- Price is -0.6% vs its 50-day average ($39.84) and +14.2% vs its 200-day average ($34.67).
- 52-week range $25.52–$43.49; today's close sits at 78% of that range, 8.9% below the 52-week high.
Oct 7, 2026 — HRMY ends flat (-0.1%) to $39.34
- Closed at $39.34, -0.05% vs the prior close of $39.36. Day range $39.10–$39.86, opened at $39.27.
- Volume was 547.00K shares, 0.6x its 50-day average of 887.76K.
- Price is -1.1% vs its 50-day average ($39.77) and +13.5% vs its 200-day average ($34.66).
- 52-week range $25.52–$43.49; today's close sits at 77% of that range, 9.5% below the 52-week high.
Oct 6, 2026 — HRMY dips 1.4% to $39.36
- Closed at $39.36, -1.40% vs the prior close of $39.92. Day range $38.91–$40.35, opened at $40.09.
- Volume was 507.30K shares, 0.6x its 50-day average of 890.09K — lighter than usual.
- Price is -0.9% vs its 50-day average ($39.70) and +13.6% vs its 200-day average ($34.65).
- 52-week range $25.52–$43.49; today's close sits at 77% of that range, 9.5% below the 52-week high.
Oct 5, 2026 — HRMY rises 0.7% to $39.92, 3 up days in a row
- Closed at $39.92, +0.71% vs the prior close of $39.64. Day range $39.51–$40.77, opened at $39.76.
- Volume was 897.90K shares, 1.0x its 50-day average of 883.84K.
- Price is +0.7% vs its 50-day average ($39.63) and +15.2% vs its 200-day average ($34.65).
- 52-week range $25.52–$43.49; today's close sits at 80% of that range, 8.2% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — HRMY ends flat (+0.2%) to $39.64
- Closed at $39.64, +0.18% vs the prior close of $39.57. Day range $39.25–$40.62, opened at $39.78.
- Volume was 916.70K shares, 1.0x its 50-day average of 881.15K.
- Price is +0.3% vs its 50-day average ($39.54) and +14.4% vs its 200-day average ($34.64).
- 52-week range $25.52–$43.49; today's close sits at 79% of that range, 8.9% below the 52-week high.
HRMY latest news & SEC filings
Every SEC filing by or about HRMY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Budur Kumar converted options/RSUs into 900 shares at $30.69 (≈$27.62K) on Sep 16, 2026; now holds 14,015
- Budur Kumar converted options/RSUs into 900 shares at $30.27 (≈$27.24K) on Sep 16, 2026; now holds 14,915
- Budur Kumar sold 1,800 shares at $43.01 (≈$77.43K) on Sep 16, 2026; now holds 13,115
- Budur Kumar converted options/RSUs into 400 shares at $30.69 (≈$12.28K) on Sep 17, 2026; now holds 13,515
- Budur Kumar converted options/RSUs into 400 shares at $30.27 (≈$12.11K) on Sep 17, 2026; now holds 13,915
- Budur Kumar sold 800 shares at $43.00 (≈$34.40K) on Sep 17, 2026; now holds 13,115
- …plus 3 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Budur Kumar sold 22,954 shares at $43.10 (≈$989.32K) on Sep 8, 2026
- Budur Kumar sold 1,000 shares at $42.79 (≈$42.79K) on Sep 8, 2026
- Budur Kumar sold 4,500 shares at $42.25 (≈$190.12K) on Sep 8, 2026
- Budur Kumar sold 22,954 shares at $43.10 (≈$989.32K) on Sep 8, 2026
- Budur Kumar sold 1,000 shares at $42.79 (≈$42.79K) on Sep 8, 2026
- Budur Kumar sold 4,500 shares at $42.25 (≈$190.12K) on Sep 8, 2026
- …plus 7 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $261.28M (prior year $200.49M) (+30.3% vs Jun 30, 2025)
- Net income: $75.43M (prior year $39.78M) (+89.6% vs Jun 30, 2025)
- Diluted EPS: $1.28 (prior year $0.68) (+88.2% vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade HRMY
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: Jul 16, 2026, May 7, 2026, Feb 24, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.44% (largest 5.1%).
- Liquidity: about 848.41K shares (≈$32.20M) trade per day on average.
- 52-week position: $37.95 vs a range of $25.52–$43.49 (69% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Kumar Budur sold 35,852 shares on Sep 18, 2026.
- Latest filings: 8-K Oct 13, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 58.24M shares outstanding (Jul 31, 2026), +1.2% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
HRMY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 38.47 | 39.00 | 37.85 | 37.95 | 892.25K |
| Oct 15, 2026 | 38.04 | 39.00 | 38.00 | 38.27 | 798.30K |
| Oct 14, 2026 | 37.16 | 38.31 | 36.92 | 37.51 | 972.20K |
| Oct 13, 2026 | 37.91 | 38.17 | 35.99 | 37.03 | 1.42M |
| Oct 12, 2026 | 38.34 | 39.89 | 37.01 | 38.23 | 1.15M |
| Oct 9, 2026 | 39.53 | 40.57 | 39.51 | 40.28 | 487.10K |
| Oct 8, 2026 | 39.14 | 39.89 | 38.68 | 39.60 | 865.00K |
| Oct 7, 2026 | 39.27 | 39.86 | 39.10 | 39.34 | 547.00K |
| Oct 6, 2026 | 40.09 | 40.35 | 38.91 | 39.36 | 507.30K |
| Oct 5, 2026 | 39.76 | 40.77 | 39.51 | 39.92 | 897.90K |
| Oct 2, 2026 | 39.78 | 40.62 | 39.25 | 39.64 | 916.70K |
| Oct 1, 2026 | 39.58 | 40.46 | 39.08 | 39.57 | 1.23M |
| Sep 30, 2026 | 39.30 | 39.56 | 38.72 | 39.26 | 667.50K |
| Sep 29, 2026 | 39.87 | 40.52 | 39.15 | 39.29 | 786.70K |
| Sep 28, 2026 | 41.29 | 41.53 | 39.53 | 40.01 | 874.40K |
| Sep 25, 2026 | 41.37 | 41.60 | 40.89 | 41.26 | 556.90K |
| Sep 24, 2026 | 40.63 | 41.79 | 40.00 | 41.16 | 906.40K |
| Sep 23, 2026 | 41.61 | 42.08 | 39.72 | 40.48 | 1.08M |
| Sep 22, 2026 | 42.10 | 42.37 | 41.36 | 41.53 | 577.90K |
| Sep 21, 2026 | 41.87 | 42.52 | 41.20 | 42.10 | 839.00K |
About Harmony Biosciences
Harmony Biosciences (HRMY) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PLYMOUTH MEETING, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1802665.
HRMY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey M. Dayno | PRESIDENT, CEO | Jan 26, 2026 |
| Geno J Germano | Director | May 18, 2026 |
| R. Mark Graf | Director | May 18, 2026 |
| Troy A. Ignelzi | Director | Apr 6, 2026 |
| Ron M Philip | Director | May 18, 2026 |
| Juan A. Sabater | Director | May 18, 2026 |
| Gary Sender | Director | May 18, 2026 |
| Linda M Szyper | Director | May 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Peter Anastasiou | CHIEF OPERATING OFFICER | Apr 6, 2026 |
| Kumar Budur | CHIEF MEDICAL OFFICER | Sep 18, 2026 |
| Jeffrey M. Dayno | PRESIDENT, CEO | Jan 26, 2026 |
| Sandip Kapadia | CHIEF FINANCIAL OFFICER | Jan 28, 2026 |
| Stephen M. Mollichella | INT PRINCIAL FINANCIAL OFFICER | Jul 22, 2026 |
| Glenn Reicin | CHIEF FINANCIAL OFFICER | May 18, 2026 |
| Andrew Serafin | CHIEF STRATEGY OFFICER | Jan 26, 2026 |
| Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | Apr 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 18, 2026 | Kumar Budur | Sale | 35,852 | $43.05 |
| Sep 18, 2026 | Kumar Budur | Sale | 35,852 | $43.05 |
| Sep 18, 2026 | Kumar Budur | Sale | 35,852 | $43.05 |
| Sep 18, 2026 | Kumar Budur | Sale | 35,852 | $43.05 |
| Sep 17, 2026 | Kumar Budur | Sale | 800 | $43.00 |
| Sep 17, 2026 | Kumar Budur | Sale | 800 | $43.00 |
| Sep 17, 2026 | Kumar Budur | Sale | 800 | $43.00 |
| Sep 17, 2026 | Kumar Budur | Sale | 800 | $43.00 |
| Sep 16, 2026 | Kumar Budur | Sale | 1,800 | $43.01 |
| Sep 16, 2026 | Kumar Budur | Sale | 1,800 | $43.01 |
| Sep 16, 2026 | Kumar Budur | Sale | 1,800 | $43.01 |
| Sep 16, 2026 | Kumar Budur | Sale | 1,800 | $43.01 |
| Sep 8, 2026 | Kumar Budur | Sale | 22,954 | $43.10 |
| Sep 8, 2026 | Kumar Budur | Sale | 1,000 | $42.79 |
| Sep 8, 2026 | Kumar Budur | Sale | 4,500 | $42.25 |
HRMY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $868.45M | $158.69M | 2.71 | $348.20M |
| Dec 31, 2024 | $714.73M | $145.49M | 2.51 | $219.82M |
| Dec 31, 2023 | $582.02M | $128.85M | 2.13 | $219.39M |
| Dec 31, 2022 | $437.86M | $181.47M | 2.97 | $144.47M |
| Dec 31, 2021 | $305.44M | $34.60M | 0.58 | $98.56M |
Latest balance sheet: total assets $1.37B, total liabilities $373.84M, cash $549.77M (as of Jun 30, 2026).
HRMY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $38.78 |
| Jul 16, 2026 | 8-K Item 2.02 (results) | $33.53 |
| May 7, 2026 | 8-K Item 2.02 (results) | $31.42 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $28.19 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $38.27 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $30.72 |
| Oct 23, 2025 | 8-K Item 2.02 (results) | $29.60 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $34.94 |
| May 6, 2025 | 8-K Item 2.02 (results) | $32.05 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $36.97 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $36.45 |
| Oct 29, 2024 | 8-K Item 2.02 (results) | $41.49 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on HRMY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.